IO Biotech Inc. has announced new severance terms for its Chief Executive Officer, Mai-Britt Zocca, following an addendum to her service agreement with the company. Under the updated terms, if the CEO's employment is terminated without cause or if she resigns for good reason, she will receive severance pay equal to 12 months of her current base salary, a prorated bonus for the year of termination, any unpaid bonus from the prior year, and accelerated vesting of equity awards scheduled to vest within 12 months. Additionally, if such a termination occurs within six months prior to or 12 months following a Change in Control, severance pay will extend to 18 months, and the bonus will not be prorated, with all outstanding equity awards fully vesting. These severance benefits are contingent upon the CEO signing a general release of claims in favor of the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。